The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMercia Asset Regulatory News (MERC)

Share Price Information for Mercia Asset (MERC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 32.70
Bid: 32.00
Ask: 33.40
Change: 0.00 (0.00%)
Spread: 1.40 (4.375%)
Open: 32.70
High: 32.70
Low: 32.70
Prev. Close: 32.70
MERC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison Investment Research Limited: Mercia Asset Management (MERC): The UK's top regional investor

3 Mar 2021 07:00

Edison Investment Research Limited Edison Investment Research Limited: Mercia Asset Management (MERC): The UK's top regional investor 03-March-2021 / 07:00 GMT/BST


 

London, UK, 3 March 2021

 

Mercia Asset Management (MERC): The UK's top regional investor

The £30.7m cash exit from Oxgene underlines management's success in building a sustainably profitable specialist asset manager, delivering high levels of contracted revenue and providing a filtered pipeline of opportunities for Mercia's direct investment portfolio. Based on progress to date, we believe Mercia will achieve its three-year strategic plan ahead of time (grow operating profitability, expand assets under management (AUM) to £1bn and 'evergreen' the balance sheet by end FY22). By the end of H121, AUM had risen to £872m (15% from FY22 target), with fee-earning funds under management (FUM) of £722m. Despite progress, Mercia's shares continue to trade at a material 21% discount to net assets (0.79x) or a 30-35% discount when we include the third-party funds business (worth 4.9p at 3% of FUM). This is a substantial discount to its peers.

 

Although profitable and dividend paying, with a mature, evergreen balance sheet, and scaling AUM, Mercia still trades at a 21% discount to its H121 NAV (34.1p per share) and a significant discount to its peers. Together with its fund management arm (5-8p per share), the overall valuation rises to 39-42p per share, implying a discount of closer to 31-36%. Catalysts for a re-rating include further scaling of the business, continuing revenue/earnings growth, commercialisation of the direct investment portfolio and/or successful exits.  

Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Richard Williamson +44 (0)20 3077 5700 tech@edisongroup.com

Rob Murphy +44 (0)20 3077 5700 tech@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-/

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1172526 03-March-2021 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
16th Aug 20187:00 amRNSnDreams secures multi-million dollar contract
7th Aug 20187:00 amRNSOG wins significant multi-million pound contract
27th Jul 20189:30 amRNSPublication of Annual Report
17th Jul 20183:14 pmRNSPDMR / Director Dealings
2nd Jul 20187:00 amRNSPreliminary Results
20th Jun 20187:00 amRNSVirtTrade secures partnership with Formula 1
12th Jun 20187:00 amRNSBoard Appointment
21st May 20187:00 amRNSNotice of Preliminary Results
17th Apr 20187:00 amRNSBoard Change
26th Mar 20187:00 amRNSDeferred Consideration and Board Change
22nd Mar 20187:00 amRNSNew Direct Investment in Voxpopme
2nd Mar 20187:00 amRNSSale of Science Warehouse Limited
1st Feb 20187:00 amRNSMercia Annual Gala Dinner
22nd Dec 20177:00 amRNSBoard Appointment
18th Dec 20177:00 amRNSAmendment to Share Options
13th Dec 20177:00 amRNS£5.0million syndicated investment into Intechnica
11th Dec 20177:00 amRNS£3.8million syndicated investment into Medherant
6th Dec 20177:00 amRNSHalf Year Results
24th Nov 20177:00 amRNSImpression Technologies secures grant funding
17th Nov 20177:00 amRNSNew Direct Investment in £5.0m syndicated round
14th Nov 20177:00 amRNSLife Sciences & Biosciences sector update
1st Nov 20177:00 amRNSNew Partnership with the University of Edinburgh
31st Oct 20177:00 amRNSNotice of Results
25th Oct 20177:00 amRNSAppointment of Joint Broker
5th Oct 20177:00 amRNSFurther significant fund realisation achieved
3rd Oct 20177:00 amRNSWebsite launch
20th Sep 20177:00 amRNS£3.1million syndicated investment
18th Sep 201711:05 amRNSResult of AGM
18th Sep 20177:00 amRNSAGM statement
21st Aug 20177:00 amRNS£2.0m investment into Oxford Genetics
2nd Aug 20177:00 amRNSBoard Change
25th Jul 20177:00 amRNSGrant Options & PDMR Dealings
21st Jul 20177:00 amRNSPublication of Annual Report
13th Jul 20177:00 amRNSMercia invests additional £2.0million into nDreams
3rd Jul 20177:00 amRNSPreliminary results
21st Jun 20177:00 amRNSInvestment into Impression Tech & Sector Update
6th Jun 20177:00 amRNSFurther investment into Oxford Genetics
3rd May 20177:00 amRNSNotice of Preliminary Results
22nd Feb 20177:00 amRNSTwo major contracts for Northern Powerhouse Funds
17th Feb 201712:00 pmRNSNotification of Major Interest in Shares
16th Feb 201710:43 amRNSResult of General Meeting & Completion of Placing
31st Jan 20172:40 pmRNSPlacing of new Ordinary Shares to raise c.£40.0m
26th Jan 20177:00 amRNSNotice of Mercia Annual Gala Dinner
18th Jan 20177:00 amRNSNew Direct Investment in Faradion Limited
16th Dec 20167:00 amRNSSale of Allinea Software Limited to ARM
16th Nov 20167:00 amRNS£1m invested in nDreams as part of £2m syndication
10th Nov 20167:00 amRNSHalf Year Results
28th Oct 20167:00 amRNSNotice of Results
27th Oct 20167:00 amRNSInvestment in Oxford Genetics Limited
19th Oct 20167:00 amRNSWarwick Audio Technologies strengthens Board

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.